OraSure Technologies (NASDAQ:OSUR) Downgraded to “Hold” Rating by StockNews.com

StockNews.com downgraded shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a research report released on Saturday morning.

OraSure Technologies Stock Performance

OraSure Technologies stock opened at $3.80 on Friday. OraSure Technologies has a fifty-two week low of $3.52 and a fifty-two week high of $8.04. The stock has a market cap of $283.44 million, a price-to-earnings ratio of 25.33 and a beta of 0.05. The stock’s 50 day simple moving average is $3.80 and its two-hundred day simple moving average is $4.03.

Institutional Trading of OraSure Technologies

Hedge funds have recently modified their holdings of the business. D. E. Shaw & Co. Inc. boosted its stake in OraSure Technologies by 180.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,517,541 shares of the medical instruments supplier’s stock worth $5,478,000 after acquiring an additional 976,475 shares in the last quarter. Renaissance Technologies LLC boosted its stake in OraSure Technologies by 23.1% during the fourth quarter. Renaissance Technologies LLC now owns 2,774,443 shares of the medical instruments supplier’s stock worth $10,016,000 after acquiring an additional 521,400 shares in the last quarter. Archon Capital Management LLC boosted its stake in OraSure Technologies by 145.1% during the fourth quarter. Archon Capital Management LLC now owns 827,777 shares of the medical instruments supplier’s stock worth $2,988,000 after acquiring an additional 490,034 shares in the last quarter. Peapod Lane Capital LLC bought a new stake in shares of OraSure Technologies in the 4th quarter worth approximately $1,730,000. Finally, Systematic Financial Management LP boosted its position in shares of OraSure Technologies by 33.7% in the 4th quarter. Systematic Financial Management LP now owns 1,673,609 shares of the medical instruments supplier’s stock worth $6,042,000 after purchasing an additional 421,497 shares in the last quarter. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.